
Avutometinib/Defactinib Appears Tolerable in KRAS-Mutant LGSOC
Rachel N. Grisham, MD, spoke with CancerNetwork® about key considerations for mitigating toxicities that may occur with avutometinib plus defactinib (Avmapki Fakzynja Co-pack) for patients with KRAS-mutated low-grade serous ovarian cancer (LGSOC) based on …